FibroBiologics (FBLG) Projected to Release Quarterly Earnings on Thursday

FibroBiologics (NASDAQ:FBLG) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect FibroBiologics to announce earnings of ($0.93) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.33) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Trading Down 11.9%

Shares of NASDAQ FBLG opened at $0.63 on Tuesday. The company has a market capitalization of $3.81 million, a P/E ratio of -0.09 and a beta of 1.14. FibroBiologics has a 12 month low of $0.62 and a 12 month high of $14.40. The stock has a 50 day moving average of $0.90 and a 200-day moving average of $3.15.

Institutional Trading of FibroBiologics

Institutional investors have recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. acquired a new position in FibroBiologics in the 3rd quarter valued at $191,000. Renaissance Technologies LLC boosted its position in shares of FibroBiologics by 287.3% in the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after acquiring an additional 171,800 shares during the period. Jane Street Group LLC bought a new stake in shares of FibroBiologics in the fourth quarter valued at about $34,000. Marshall Wace LLP acquired a new position in shares of FibroBiologics in the second quarter valued at about $49,000. Finally, Geode Capital Management LLC grew its stake in shares of FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after acquiring an additional 59,813 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Wall Street Zen raised FibroBiologics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Maxim Group downgraded shares of FibroBiologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. HC Wainwright restated a “buy” rating and set a $8.00 target price (up from $4.00) on shares of FibroBiologics in a research note on Thursday, April 16th. Finally, Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, FibroBiologics currently has a consensus rating of “Hold” and an average price target of $74.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.